Over 5,400 participants will gather to learn the latest intensive care medicine findings in a growing event with more than 60 exhibitors, 20 satellite symposia and over 1,300 submitted abstratcs.

NGAL and The NGAL Test

NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal status markers and has a proportionate response to injury.

ESICM 2010 is an outstanding occasion to promote The NGAL Test - the company’s forthcoming clinical chemistry test for the diagnosis and management of acute kidney injury.

The NGAL Test will be available for a wide range of clinical chemistry analyzers and will be launched in the beginning of 2011. The NGAL Test will be able to determine NGAL levels in both urine and plasma within a standard routine timeframe.

For more information or to set up an appointment, please contact:

Klaus Boberg Pedersen, Human Diagnostics Product Manager, kbp@bioporto.com

Jakob Ohm Eriksen, Pharma Diagnostics Product Manager, joe@bioporto.com

Further information on ESICM 2010 is available at: http://www.esicm.org/Data/ModuleGestionDeContenu/PagesGenerees/07-congresses/0A-annual-congress/105.asp